NIH Myeloid Malignancy Program

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

We shared several reviews in this area over the last year. This includes the following: Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges; Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future; Overcoming challenges in Myelodysplastic Syndromes therapy advances; Advancing drug development in myelodysplastic syndromes. Challenges to advancing drug development in MDS are multifold but may be grouped into specific categories, including criteria for risk stratification and eligibility, response definitions, time-to-event end points, transfusion end points, functional assessments, and biomarker development. Strategies to address these challenges and optimize future clinical trial design for patients with MDS are discussed.